Comparative efficacy and safety of Chinese medicine injections as an adjunctive therapy for cervical cancer in Chinese patients: a network meta-analysis
Chinese medicine injections (CMIs) are widely used as adjuvant therapy for cervical cancer in China. However, the effectiveness of different types of CMIs remains uncertain. To assess the effectiveness and safety of CMIs when used in conjunction with radiotherapy (RT) or concurrent chemoradiotherapy (CCRT), particularly in combination with cisplatin (DDP), docetaxel plus cisplatin (DP), and paclitaxel plus cisplatin (TP). Randomized controlled trials (RCTs) were searched in databases including CNKI, WanFang, VIP, SinoMed, PubMed, Cochrane Library, Embase, and Web of Science from inception to September 2023. We calculated the risk ratio with a 95% confidence interval and the surface under the cumulative ranking area curve (SUCRA) for the clinical efficacy rate (CER), the efficacy rate by Karnofsky Performance Status (KPS), and the rates of leukopenia reduction (LRR) and gastrointestinal reactions (GRR). Forty-seven RCTs were included, including nine CMI types: The optimal recommendation depends on whether CMIs are used with radiotherapy or concurrent chemoradiotherapy. More high-quality RCTs are needed to confirm further and update the existing evidence.
Journal
Pharmaceutical BiologyAuthors
Funding
High Level Talent Cultivation Project of Traditional Chinese Medicine of Shandong Province FundingProject of National Traditional Chinese Medicine Characteristic Technology Inheritance Talent FundingProject of National Famous and Old Traditional Chinese Medicine Expert ZHANG Hongxing Inheritance Studio FundingProject of National Old Traditional Chinese Medicine Expert LIU Xianghong Inheritance FundingNatural Science Foundation of Shandong Province Grant ZR2019MH063Natural Science Foundation of Shandong Province Grant 2019GNC21307Natural Science Foundation of Shandong Province Grant 2019-0208, 2019-0215, 2019-0914, 2017-114